Skip to main content

Advertisement

SpringerLink
Log in

Neuropsychiatric aspects of Parkinson’s disease

  • Neurology and Preclinical Neurological Studies - Review Article
  • Published:
Journal of Neural Transmission Aims and scope Submit manuscript

Abstract

Throughout the natural history of Parkinson’s Disease (PD), from the pre-diagnostic phase to end stage disease, neuropsychiatric manifestations represent a core feature of the disease. This review summarises current knowledge on the features of depression, anxiety, apathy, fatigue, impulse control disorders (ICDs) and psychosis in PD. These co-morbidities are common and still frequently under-recognised. Their impact on quality of life is considerable, with depression having been shown to be the main determinant of health-related quality of life in PD patients. As well as formal diagnostic criteria, multiple scales have been developed to allow for assessment of these symptoms in both the clinic and research settings. The evidence base for treatment is variable, with increasing evidence for pharmacological and non-pharmacological treatment options for depression, but less robust evidence for the treatment of other neuropsychiatric features. Imaging studies are increasingly providing insight into the neural basis of these symptoms, with the hope that this insight will translate into treatments that can benefit patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Abbes M et al (2018) Subthalamic stimulation and neuropsychiatric symptoms in Parkinson’s disease: results from a long-term follow-up cohort study. J Neurol Neurosurg Psychiatr 89:836–843

    Article  Google Scholar 

  • Barone P et al (2009) The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord 24:1641–1649

    Article  PubMed  Google Scholar 

  • Barone P et al (2010) Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 9:573–580

    Article  CAS  PubMed  Google Scholar 

  • Bower JH et al (2010) Anxious personality predicts an increased risk of Parkinson’s disease. Mov Disord 25:2105–2113

    Article  PubMed  PubMed Central  Google Scholar 

  • Broen MPG, Narayen NE, Kuijf ML, Dissanayaka NNW, Leentjens AFG (2016) Prevalence of anxiety in Parkinson’s disease: a systematic review and meta-analysis. Mov Disord 31:1125–1133

    Article  PubMed  Google Scholar 

  • Brown RG et al (2011) Depression and anxiety related subtypes in Parkinson’s disease. J Neurol Neurosurg Psychiatr 82:803–809

    Article  Google Scholar 

  • Burn D et al (2006) Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson’s disease. Mov Disord 21:1899–1907

    Article  PubMed  Google Scholar 

  • Burn DJ et al (2012) Parkinson’s disease motor subtypes and mood. Mov Disord 27:379–386

    Article  PubMed  Google Scholar 

  • Cohen ML, Aita S, Mari Z, Brandt J (2015) The unique and combined effects of apathy and depression on cognition in Parkinson’s disease. J Parkinsons Dis 5:351–359

    Article  PubMed  Google Scholar 

  • Corbin L et al (2016) Acupuncture for symptomatic treatment of fatigue in Parkinson’s disease: trial design and implementation. Med Acupunct 28:194–205

    Article  PubMed  PubMed Central  Google Scholar 

  • Cummings J et al (2014) Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet 383:533–540

    Article  CAS  PubMed  Google Scholar 

  • Czernecki V et al (2008) Apathy following subthalamic stimulation in Parkinson disease: a dopamine responsive symptom. Mov Disord 23:964–969

    Article  PubMed  Google Scholar 

  • Devos D et al (2014) Rivastigmine in apathetic but dementia and depression-free patients with Parkinson’s disease: a double-blind, placebo-controlled, randomised clinical trial. J Neurol Neurosurg Psychiatr 85:668–674

    Article  Google Scholar 

  • Drijgers RL, Dujardin K, Reijnders JSAM, Defebvre L, Leentjens AFG (2010) Validation of diagnostic criteria for apathy in Parkinson’s disease. Parkinsonism Relat Disord 16:656–660

    Article  PubMed  Google Scholar 

  • Egan SJ, Laidlaw K, Starkstein S (2015) Cognitive behaviour therapy for depression and anxiety in Parkinson’s disease. J Parkinsons Dis 5:443–451

    Article  PubMed  PubMed Central  Google Scholar 

  • Fang F et al (2010) Depression and the subsequent risk of Parkinson’s disease in the NIH-AARP Diet and Health Study. Mov Disord 25:1157–1162

    Article  PubMed  PubMed Central  Google Scholar 

  • Fantini ML et al (2018) Sleep and REM sleep behaviour disorder in Parkinson’s disease with impulse control disorder. J Neurol Neurosurg Psychiatr 89:305–310

    Article  Google Scholar 

  • Feldmann A et al (2008) Morphometric changes of gray matter in Parkinson’s disease with depression: a voxel-based morphometry study. Mov Disord 23:42–46

    Article  PubMed  Google Scholar 

  • Fénelon G, Alves G (2010) Epidemiology of psychosis in Parkinson’s disease. J Neurol Sci 289:12–17

    Article  PubMed  Google Scholar 

  • Ffytche DH, Aarsland D (2017) Psychosis in Parkinson’s disease. Int Rev Neurobiol 133:585–622

    Article  PubMed  Google Scholar 

  • Forjaz MJ et al (2015) Is the Parkinson anxiety scale comparable across raters? Mov Disord 30:545–551

    Article  PubMed  Google Scholar 

  • Friedman JH, Friedman H (2001) Fatigue in Parkinson’s disease: a nine-year follow-up. Mov Disord 16:1120–1122

    Article  CAS  PubMed  Google Scholar 

  • Gallagher DA, Schrag A (2012) Psychosis, apathy, depression and anxiety in Parkinson’s disease. Neurobiol Dis 46:581–589

    Article  PubMed  Google Scholar 

  • Gallagher DA, Parkkinen L, O'Sullivan SS, Spratt A, Shah A, Davey CC, Bremner FD, Revesz T, Williams DR, Lees AJ, Schrag A (2011) Testing an aetiological model of visual hallucinations in Parkinson’s disease. Brain 134(Pt 11):3299–3309

    Article  PubMed  Google Scholar 

  • Goetz CG, Stebbins GT (1995) Mortality and hallucinations in nursing home patients with advanced Parkinson’s disease. Neurology 45:669–671

    Article  CAS  PubMed  Google Scholar 

  • Gou L et al (2018) Structural brain network alteration and its correlation with structural impairments in patients with depression in de novo and Drug-Naïve Parkinson’s disease. Front Neurol 9:608

    Article  PubMed  PubMed Central  Google Scholar 

  • Harding AJ, Broe GA, Halliday GM (2002) Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain 125:391–403

    Article  CAS  PubMed  Google Scholar 

  • Jason LA, Evans M, Brown M, Porter N (2010) What is fatigue? pathological and nonpathological fatigue. PM R 2:327–331

    Article  PubMed  Google Scholar 

  • Kluger BM et al (2016) Parkinson’s disease-related fatigue: a case definition and recommendations for clinical research. Mov Disord 31:625–631

    Article  PubMed  PubMed Central  Google Scholar 

  • Kritzinger C et al (2015) Qualitative characteristics of depression in Parkinson’s patients and controls. Behav Neurol 2015:961372–961375

    Article  PubMed  PubMed Central  Google Scholar 

  • Lee Y et al (2018) The presence of depression in de novo Parkinson’s disease reflects poor motor compensation. PLoS One 13:e0203303

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lee J-Y et al (2019) Behavioural and trait changes in parkinsonian patients with impulse control disorder after switching from dopamine agonist to levodopa therapy: results of REIN-PD trial. J Neurol Neurosurg Psychiatr 90:30–37

    Article  Google Scholar 

  • Leentjens AFG et al (2008) Apathy and anhedonia rating scales in Parkinson’s disease: critique and recommendations. Mov Disord 23:2004–2014

    Article  PubMed  Google Scholar 

  • Leentjens AF, Dujardin K, Pontone GM, Starkstein SE, Weintraub D, Martinez-Martin P (2014) The Parkinson Anxiety Scale (PAS): development and validation of a new anxiety scale. Mov Disord 29(8):1035–1043

    Article  PubMed  Google Scholar 

  • Li Y et al (2014) Clinicogenetic study of GBA mutations in patients with familial Parkinson’s disease. Neurobiol Aging 35(935):e3–e8

    Google Scholar 

  • Li D-K et al (2018) Depressive symptoms are associated with color vision but not olfactory function in patients with Parkinson’s disease. J Neuropsychiatry Clin Neurosci 30:122–129

    Article  PubMed  Google Scholar 

  • Lim TT et al (2015) Rasagiline for the symptomatic treatment of fatigue in Parkinson’s disease. Mov Disord 30:1825–1830

    Article  CAS  PubMed  Google Scholar 

  • Maillet A et al (2016) The prominent role of serotonergic degeneration in apathy, anxiety and depression in de novo Parkinson’s disease. Brain 139:2486–2502

    Article  PubMed  Google Scholar 

  • Marsh L, McDonald WM, Cummings J, B.NINDS/NIMH Work Group on Depression and Parkinson’s Disease (2006) Ravina, Provisional diagnostic criteria for depression in Parkinson’s disease: report of an NINDS/NIMH Work Group. Mov Disord 21:148–158

    Article  PubMed  Google Scholar 

  • Martinez-Martin P et al (2016) Accuracy of screening instruments for detection of neuropsychiatric syndromes in Parkinson’s disease. Mov Disord 31:270–279

    Article  PubMed  Google Scholar 

  • Martini A, Dal Lago D, Edelstyn NMJ, Grange JA, Tamburin S (2018) Impulse control disorder in Parkinson’s disease: a meta-analysis of cognitive, affective, and motivational correlates. Front Neurol 9:654

    Article  PubMed  PubMed Central  Google Scholar 

  • Mayberg HS et al (1990) Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson’s disease. Ann Neurol 28:57–64

    Article  CAS  PubMed  Google Scholar 

  • Meco G, Bernardi S (2007) Antidepressant use in treatment of psychosis with comorbid depression in Parkinson’s disease. Prog Neuropsychopharmacol Biol Psychiatry 31:311–313

    Article  CAS  PubMed  Google Scholar 

  • Mondolo F et al (2007) Evaluation of anxiety in Parkinson’s disease with some commonly used rating scales. Neurol Sci 28:270–275

    Article  CAS  PubMed  Google Scholar 

  • Nassif DV, Pereira JS (2018) Fatigue in Parkinson’s disease: concepts and clinical approach. Psychogeriatrics 18:143–150

    Article  PubMed  Google Scholar 

  • Nilsson FM, Kessing LV, Sørensen TM, Andersen PK, Bolwig TG (2002) Major depressive disorder in Parkinson’s disease: a register-based study. Acta Psychiatr Scand 106:202–211

    Article  PubMed  Google Scholar 

  • Nomura T et al (2003) Visual hallucinations as REM sleep behavior disorders in patients with Parkinson’s disease. Mov Disord 18:812–817

    Article  PubMed  Google Scholar 

  • O’Callaghan C, Hornberger M (2013) Screening for impulse control symptoms in patients with de novo Parkinson disease: a case-control study. Neurology 81:694–695

    Article  PubMed  Google Scholar 

  • Okai D et al (2013) Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers. Neurology 80:792–799

    Article  PubMed  PubMed Central  Google Scholar 

  • Papay K et al (2011) Patient versus informant reporting of ICD symptoms in Parkinson’s disease using the QUIP: validity and variability. Parkinsonism Relat Disord 17:153–155

    Article  PubMed  Google Scholar 

  • Phu AL et al (2014) Effect of impulse control disorders on disability and quality of life in Parkinson’s disease patients. J Clin Neurosci 21:63–66

    Article  PubMed  Google Scholar 

  • Picillo M et al (2017) Association between dopaminergic dysfunction and anxiety in de novo Parkinson’s disease. Parkinsonism Relat Disord 37:106–110

    Article  PubMed  Google Scholar 

  • Pilling S et al (2009) Depression in adults, including those with a chronic physical health problem: summary of NICE guidance. BMJ 339:b4108–b4108

    Article  PubMed  PubMed Central  Google Scholar 

  • Poletti M, De Rosa A, Bonuccelli U (2012) Affective symptoms and cognitive functions in Parkinson’s disease. J Neurol Sci 317:97–102

    Article  PubMed  Google Scholar 

  • Pontieri FE et al (2015) Sociodemographic, neuropsychiatric and cognitive characteristics of pathological gambling and impulse control disorders NOS in Parkinson’s disease. Eur Neuropsychopharmacol 25:69–76

    Article  CAS  PubMed  Google Scholar 

  • Politis M, Loane C (2011) Serotonergic Dysfunction in Parkinson's Disease and Its Relevance to Disability. Sci World J 11:1726–1734

    Article  CAS  Google Scholar 

  • Pont-Sunyer C et al (2015) The onset of nonmotor symptoms in Parkinson’s disease (the ONSET PD study). Mov Disord 30:229–237

    Article  PubMed  Google Scholar 

  • Quelhas R, Costa M (2009) Anxiety, depression, and quality of life in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 21:413–419

    Article  PubMed  Google Scholar 

  • Qureshi SU, Amspoker AB, Calleo JS, Kunik ME, Marsh L (2012) Anxiety disorders, physical illnesses, and health care utilization in older male veterans with Parkinson disease and comorbid depression. J Geriatr Psychiatry Neurol 25:233–239

    Article  PubMed  Google Scholar 

  • Ravina B et al (2007) Diagnostic criteria for psychosis in Parkinson’s disease: report of an NINDS, NIMH work group. Mov Disord 22:1061–1068

    Article  PubMed  Google Scholar 

  • Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF (2008) A systematic review of prevalence studies of depression in Parkinson’s disease. Mov Disord 23:183–189

    Article  PubMed  Google Scholar 

  • Reijnders JSAM et al (2010) Neuroanatomical correlates of apathy in Parkinson’s disease: a magnetic resonance imaging study using voxel-based morphometry. Mov Disord 25:2318–2325

    Article  PubMed  Google Scholar 

  • Remy P, Doder M, Lees A, Turjanski N, Brooks D (2005) Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 128(Pt 6):1314–1322

    Article  PubMed  Google Scholar 

  • Richard IH, Justus AW, Kurlan R (2001) Relationship between mood and motor fluctuations in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 13:35–41

    Article  CAS  PubMed  Google Scholar 

  • Robert P et al (2009) Proposed diagnostic criteria for apathy in Alzheimer’s disease and other neuropsychiatric disorders. Eur Psychiatry 24:98–104

    Article  CAS  PubMed  Google Scholar 

  • Samuel M et al (2015) Management of impulse control disorders in Parkinson’s disease: controversies and future approaches. Mov Disord 30:150–159

    Article  PubMed  PubMed Central  Google Scholar 

  • Santangelo G et al (2013) Apathy in Parkinson’s disease: diagnosis, neuropsychological correlates, pathophysiology and treatment. Behav Neurol 27:501–513

    Article  PubMed  PubMed Central  Google Scholar 

  • Schifitto G et al (2008) Fatigue in levodopa-naive subjects with Parkinson disease. Neurology 71:481–485

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Schrag A (2006) Quality of life and depression in Parkinson’s disease. J Neurol Sci 248:151–157

    Article  PubMed  Google Scholar 

  • Schrag A, Politis M (2016) Serotonergic loss underlying apathy in Parkinson’s disease. Brain 139:2338–2339

    Article  PubMed  Google Scholar 

  • Schrag A, Horsfall L, Walters K, Noyce A, Petersen I (2017) Prediagnostic presentations of Parkinson’s disease in primary care: a case-control study. Lancet Neurol 14:57–64

    Article  PubMed  Google Scholar 

  • Seppi K et al (2011) The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord 26(Suppl 3):S42–S80

    Article  PubMed  PubMed Central  Google Scholar 

  • Seppi K et al (2019) Update on treatments for nonmotor symptoms of Parkinson’s disease-an evidence-based medicine review. Mov Disord 34:180–198

    Article  PubMed  PubMed Central  Google Scholar 

  • Sherbaf FG, Same K, Aarabi MH (2018) High angular resolution diffusion imaging correlates of depression in Parkinson’s disease a connectometry study. Acta Neurol Belg 118:573–579

    Article  Google Scholar 

  • Siciliano M et al (2018) Fatigue in Parkinson’s disease: a systematic review and meta-analysis. Mov Disord 33:1712–1723

    Article  PubMed  Google Scholar 

  • Starkstein SE, Leentjens AFG (2008) The nosological position of apathy in clinical practice. J Neurol Neurosurg Psychiatr 79:1088–1092

    Article  CAS  Google Scholar 

  • Starkstein SE et al (1992) Reliability, validity, and clinical correlates of apathy in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 4:134–139

    Article  CAS  PubMed  Google Scholar 

  • Starkstein SE, Robinson RG, Leiguarda R, Preziosi TJ (1993) Anxiety and depression in Parkinson’s disease. Behav Neurol 6:151–154

    Article  CAS  PubMed  Google Scholar 

  • Steeves TDL et al (2009) Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. Brain 132:1376–1385

    Article  CAS  PubMed  Google Scholar 

  • Stocchi F, ADAGIO investigators (2014) Benefits of treatment with rasagiline for fatigue symptoms in patients with early Parkinson’s disease. Eur J Neurol 21:357–360

    Article  CAS  PubMed  Google Scholar 

  • Thobois S et al (2013) Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil. Brain 136:1568–1577

    Article  PubMed  Google Scholar 

  • Timmer MHM, van Beek MHCT, Bloem BR, Esselink RAJ (2017) What a neurologist should know about depression in Parkinson’s disease. Pract Neurol 17:359–368

    Article  PubMed  Google Scholar 

  • Ueda S, Koyama K, Okubo Y (2010) Marked improvement of psychotic symptoms after electroconvulsive therapy in Parkinson disease. J ECT 26:111–115

    Article  PubMed  Google Scholar 

  • Voon V, Fox S, Butler TR, Lang AE (2007) Antidepressants and psychosis in Parkinson disease: a case series. Int J Geriatr Psychiatry 22:601–604

    Article  PubMed  Google Scholar 

  • Vriend C et al (2014) Depression and impulse control disorders in Parkinson’s disease: two sides of the same coin? Neurosci Biobehav Rev 38:60–71

    Article  PubMed  Google Scholar 

  • Vriend C et al (2016) A smaller amygdala is associated with anxiety in Parkinson’s disease: a combined FreeSurfer-VBM study. J Neurol Neurosurg Psychiatr 87:493–500

    Article  Google Scholar 

  • Weintraub D, Claassen DO (2017) Impulse control and related disorders in Parkinson’s disease. Int Rev Neurobiol 133:679–717

    Article  PubMed  Google Scholar 

  • Weintraub D et al (2010a) Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Ann Neurol 68:963–968

    Article  PubMed  Google Scholar 

  • Weintraub D et al (2010b) Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 67:589–595

    Article  PubMed  Google Scholar 

  • Weintraub D, Papay K, Xie SX (2015) Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study. Neurology 84:1386–1387

    Article  PubMed  Google Scholar 

  • Williams DR, Lees AJ (2005) Visual hallucinations in the diagnosis of idiopathic Parkinson’s disease: a retrospective autopsy study. Lancet Neurol 4:605–610

    Article  PubMed  Google Scholar 

  • Zhu K, van Hilten JJ, Marinus J (2017) Onset and evolution of anxiety in Parkinson’s disease. Eur J Neurol 24:404–411

    Article  CAS  PubMed  Google Scholar 

  • Zurowski M, O’Brien JD (2015) Developments in impulse control behaviours of Parkinson’s disease. Curr Opin Neurol 28:387–392

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical and Movement Neurosciences, UCL Institute of Neurology, University College London, London, NW3 2PF, UK

    Anna Nagy & Anette Schrag

Authors
  1. Anna Nagy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anette Schrag
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anette Schrag.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nagy, A., Schrag, A. Neuropsychiatric aspects of Parkinson’s disease. J Neural Transm 126, 889–896 (2019). https://doi.org/10.1007/s00702-019-02019-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00702-019-02019-7

Keywords

Search

Navigation